Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742043 | 0.91 | LRRK2 (0.43) | UTS2RLRRK2KDRMETAXL | |
| SCHEMBL1741953 | 0.89 | UTS2R (0.49) | UTS2RKMT2AKDRMETAXL | |
| SCHEMBL1743431 | 0.87 | KCNA5 (0.45) | ALDH1A1HPGDKMT2ANPSR1KDR | |
| SCHEMBL1743441 | 0.85 | POLB (0.48) | UTS2RKDRMETAXLDYRK1A | |
| SCHEMBL1743562 | 0.84 | MET (0.45) | UTS2RLRRK2ALDH1A1KDRMET | |
| SCHEMBL2838272 | 0.83 | MET (0.51) | KDRMETAXLRETFLT3 | |
| SCHEMBL1742091 | 0.82 | MET (0.44) | UTS2RKDRMETAXLRET | |
| SCHEMBL1741332 | 0.81 | KDM4E (0.48) | LRRK2ALDH1A1KDRMETAXL | |
| SCHEMBL1742662 | 0.80 | STK4 (0.47) | UTS2RLRRK2KDRMETAXL | |
| SCHEMBL1742647 | 0.79 | MET (0.55) | KDRMETAXLRETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | claimed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | claimed |
| US-8975407-B2 | α7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2015-03-10 | — | — | US | disclosed |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ANVYL LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-8563579-B2 | α-7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof | ANVYL LLC (US) | 2013-10-22 | — | — | US | disclosed |
| EP-2387575-B1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL LLC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-2387575-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | Anvyl, LLC (US) | 2011-11-23 | — | — | EP | disclosed |
| US-D647030-S1 | Automobile tire tread | THE YOKOHAMA RUBBER CO., LTD (JP) | 2011-10-18 | — | — | US | disclosed |
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | ALPHARMAGEN LLC | 2010-07-29 | — | — | US | disclosed |
| WO-2010083444-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | ANVYL, LLC (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190819-A1 | alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | UTS2R 613/4885LRRK2 2344/4885CA12 3482/4885 |
| US-20140194462-A1 | Alpha-7 Nicotinic Acetylcholine Receptor Allosteric Modulators, Their Derivatives and Uses Thereof | CHRNA7, CHRNA1, CHRNG | UTS2R 613/4885LRRK2 2344/4885CA12 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.